Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

More targeted therapy or focus on chemotherapy after acquired resistance to a targeted therapy? How might we decide?
Author
Howard (Jack) West, MD

One of the challenges we face now when a patient with a "driver mutation" like an EGFR mutation or an ALK rearrangement develops progression on a targeted therapy against that particular target is whether to continue on another agent that might work specifically against that target or switch to a less specific approach, like chemotherapy or immunotherapy, which haven't been demonstrated to be more or less effective against a specific molecularly defined subgroup.  The short answer is that there is no clear answer, no best way to proceed, but I would say that there are some sensible principles on which many of the specialists agree.  Here are the key principles I use in making a recommendation for pursuing another line of treatment against the same target vs. changing direction.

1) How good and how long was the response to initial targeted therapy? Even in two people who have an EGFR mutation, for instance, one might have a remarkable response to Tarceva (erlotinib) that lasts for 18 months, while another may have stable disease for a few months and then progression just 4 months after starting it.  I'd be far more inclined to consider further EGFR-directed therapies for the great responder.  You might well surmise that the person who had a rather disappointing and short-lived response to the initial targeted therapy is generally not going to do better with the second agent against that same target.

2) Is there a good suggestion of a subpopulation of cancer that is still responsive to the targeted therapy? Sometimes, a person will have 80% of their disease melt away on targeted therapy and then show steady progression but still have much less cancer even after months of progression than they started with.  Others may have had their targeted therapy stopped and then developed rapid acceleration of their disease ("flare reaction" or "rebound progression").  Both of these situations suggest that there is still significant disease that remains responsive to inhibition of that target, so either adding a new therapy to ongoing targeted therapy (even the same one on which a patient has been progressing) or a switch to a new inhibitor of the same target may be especially appealing.

3) How promising are the subsequent targeted therapy options? For instance, there are several second line ALK inhibitors such as LDK-378 from Norvartis and Ariad's AP26113 that have demonstrated response rates in XALKORI (crizotinib)-pretreated patients that look as good as the results seen in in XALKORI-naive patients, and the second generation agents appear to also potentially work against brain metastases.  On the other hand, the results with Gilotrif (afatinib) for patients with an EGFR mutation and acquired resistance to Tarceva (erlotinib) have been less impressive (perhaps more favorable when this agent is combined with Erbitux (cetuximab), though tolerability is a major question).  All else being equal, I'm more inclined to favor another targeted therapy effort when the evidence is promising for subsequent targeted therapies.

4) How appealing is the non-targeted therapy option?  For those who are chemo-naive or who had a nice response to it previously, chemotherapy may pose a very significant chance of benefit that eclipses a very small probability of response to an unproven or dubiously effective targeted therapy like single-agent afatinib.  Others may have progressed through prior chemo or have received many lines of prior chemo, in which case the probability of benefit from more chemo is vanishingly small.

5) Are there toxicity factors or other personal issues? Some people may be battle-worn from a lot of prior chemotherapy, with blood counts that have required extra weeks to recover from prior chemo. Some people may say they absolutely want to avoid more chemo.  Some people may have a much easier or harder time traveling to the site of a clinical trial.  Obviously, all of these factors are part of the equation.  

To summarize, the idea is just to get a sense of how promising the different options are in general (has the next targeted therapy worked in many people? Is the next potential chemo option known to be active and prolong survival in a broader population), and then to individualize the decision for the particular patient based on the hints of how effective or ineffective targeted therapy or less targeted therapy have been in the past. 

I hope that's helpful. I'm happy to address any general questions (just please don't ask me what you personally should do).

Next Previous link

Previous PostNext Post

Related Content

Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.
Image
Terapias Dirigidas de Cancer de Pulmón 2024
Video
La Dra. Estelamari Rodríguez presenta información básica sobre el NSCLC EGFR+ y analiza la importancia de las pruebas de biomarcadores en el cáncer de pulmón y ofrece una descripción general de las opciones de tratamiento para la enfermedad EGFR+.  Para ver la playlist completa, de click aquí.        

Forum Discussions

Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...

Hi Bluebird,  Welcome to GRACE.  I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had. 

 

A CT would be...

Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...

Hi and welcome to GRACE.  I'm sorry to know you are entering a new stage.  I'm not about to comment just now but wanted to let you know I see your...

Edit to say, we can't give advice but we can comment with views and facts.  :)

 

My first thought is to ask if she has been seen at a large...

Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...

Recent Comments

JOIN THE CONVERSATION
Tagrix FDA Approval
By mariachristian on
Hi Judy! It is so good to…
By JanineT GRACE … on
Tagrix vs Tagrisso
By Dipakchavan on
Hello Linda, my name is…
By AlexandraGBeneke on